Abstract 4482
Background
Cancer and the adverse events of its treatment influence patients’ psychology and decrease their quality of life. The aim of this study was the investigation of the relationship between anxiety, depression and quality of life of ambulatory cancer patients undergoing chemotherapy.
Methods
This cross-sectional study was conducted in the one-day clinic of a large anticancer Hospital in Athens, Greece. Our convenience heterogeneous sample included 150 patients who received chemotherapy. Participants completed the Distress Thermometer and Problem List, the Hospital Anxiety and Depression Scale (HADS), the EORTC QLQ-C30 (version 3.0) for the assessment of Quality of life and the demographic and clinical characteristics questionnaire. Permission for the research was obtained by the ethical committee of the hospital. Data analysis was conducted by SPSS 22.0. The statistical significance level was set at p < 0.05.
Results
The mean age of the participants was 60.07±11.42 while 64% of the sample was female. The majority of patients reported worry (82.7%), fatigue (84.7%), fear (74.7%), nervousness, (51.3%) sadness (51.3%) and depression (34%). Female patients reported higher distress levels than male (p < 0,005). The participants’ educational level was found to correlate significantly with the cognitive functioning (p = 0.017) and financial impact (p = 0.026) subscales. Statistically significant positive correlations were found between HADS-anxiety and HADS-depression and symptom subscales of the EORTC QLQ-C30 questionnaire (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbances, appetite loss and financial impact). Statistically significant negative correlations were also found between HADS-anxiety and HADS-depression and the functional subscales of the EORTC QLQ-C30 questionnaire (physical, role, emotional, cognitive and social functioning).
Conclusions
Anxiety and depression have a negative influence on the quality of life of ambulatory cancer patients during chemotherapy. Nurses could play an important role in the recognition and management of these symptoms. Academics and nurse managers professionals need to enhance nurses’ knowledge and sensitivity and empower them to take an active role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Program of Postgraduate Studies in "Neurological Disorders - Evidence Based Practice", Nursing Department, University of West Attica, Athens, Greece.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract